| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2020.01.005 |
| P698 | PubMed publication ID | 31932108 |
| P50 | author | Gordon C. Jayson | Q37839060 |
| Susana Banerjee | Q90408920 | ||
| P2093 | author name string | Sarah Taylor | |
| Caroline Dive | |||
| Alexander R Lyon | |||
| Cong Zhou | |||
| Jonathan Tugwood | |||
| Gordon J S Rustin | |||
| Marcia Hall | |||
| Andrew R Clamp | |||
| Robert D Morgan | |||
| Cecilia Orbegoso | |||
| Jurjees Hasan | |||
| P2860 | cites work | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results | Q33149039 | ||
| Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow | Q33150747 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer | Q34134697 | ||
| Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum | Q34185144 | ||
| Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. | Q34520190 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab | Q37100738 | ||
| Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study | Q37130150 | ||
| Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). | Q37832624 | ||
| Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. | Q40228810 | ||
| Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. | Q42203168 | ||
| Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate | Q44478859 | ||
| Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging | Q44478862 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| A dose-escalation study of combretastatin A4-phosphate in healthy dogs. | Q48268319 | ||
| Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. | Q52620379 | ||
| Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. | Q52625890 | ||
| Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. | Q55041853 | ||
| Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats | Q58596237 | ||
| Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer | Q58599860 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial | Q89170919 | ||
| P433 | issue | 3 | |
| P921 | main subject | ovarian cancer | Q172341 |
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 545-551 | |
| P577 | publication date | 2020-01-10 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial | |
| P478 | volume | 156 |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | cites work | P2860 |
Search more.